Bharat Immunologicals & Biologicals
BSE: BIBCL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Bharat Immunologicals & Biologicals's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bharat Immunologicals and Biologicals Corporation Limited (BIBCL) is a central public sector undertaking focused on manufacturing high-quality vaccines and pharmaceutical formulations for national health programs. The company primarily produces Oral Polio Vaccines, zinc tablets, and Diarrhea Management Kits to support public health initiatives in India.
Business Model
BIBCL operates as a government-backed entity, generating revenue primarily through the supply of essential vaccines and pharmaceutical products to the Government of India for national immunization and health programs.
Management Commentary
Management focuses on maintaining international manufacturing standards to ensure the efficacy and safety of vaccines supplied for national health eradication efforts.
Growth Outlook
Growth is driven by the continued demand for essential pharmaceutical formulations and the potential expansion of the company's product portfolio within the public health sector.
Key Risks
- Policy Dependency. The company's revenue is highly dependent on government procurement policies and national health program budgets.
- Regulatory Compliance. Strict adherence to international manufacturing standards and evolving pharmaceutical regulations is critical for operational continuity.
- Product Concentration. Heavy reliance on a limited portfolio, particularly Oral Polio Vaccines, exposes the company to risks associated with shifting disease prevalence and immunization strategies.
Start your research today
Unlock AI insights, financials, peers and live data on Bharat Immunologicals & Biologicals and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Bharat Immunologicals & BiologicalsBIBCL | ₹68 Cr | — | — | — | -41.0% | — | — | -26.4% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2023
Financials
Bharat Immunologicals & Biologicals
BSE: BIBCL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Bharat Immunologicals & Biologicals's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bharat Immunologicals and Biologicals Corporation Limited (BIBCL) is a central public sector undertaking focused on manufacturing high-quality vaccines and pharmaceutical formulations for national health programs. The company primarily produces Oral Polio Vaccines, zinc tablets, and Diarrhea Management Kits to support public health initiatives in India.
Business Model
BIBCL operates as a government-backed entity, generating revenue primarily through the supply of essential vaccines and pharmaceutical products to the Government of India for national immunization and health programs.
Management Commentary
Management focuses on maintaining international manufacturing standards to ensure the efficacy and safety of vaccines supplied for national health eradication efforts.
Growth Outlook
Growth is driven by the continued demand for essential pharmaceutical formulations and the potential expansion of the company's product portfolio within the public health sector.
Key Risks
- Policy Dependency. The company's revenue is highly dependent on government procurement policies and national health program budgets.
- Regulatory Compliance. Strict adherence to international manufacturing standards and evolving pharmaceutical regulations is critical for operational continuity.
- Product Concentration. Heavy reliance on a limited portfolio, particularly Oral Polio Vaccines, exposes the company to risks associated with shifting disease prevalence and immunization strategies.
Start your research today
Unlock AI insights, financials, peers and live data on Bharat Immunologicals & Biologicals and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2023